非索非那定与西替利嗪治疗过敏性鼻炎疗效及安全性的Meta分析

发布时间：2018-09-19 15:33

【摘要】：目的系统评价非索非那定与西替利嗪治疗过敏性鼻炎(AR)的疗效和安全性。方法计算机检索Pub Med、EMBase、Cochrane Library、中国知网、维普网和万方数据知识服务平台中关于非索非那定(试验组)与西替利嗪(对照组)治疗AR的临床随机对照试验(RCT),检索时间为建库至2016-06-10,根据Cochrane系统评价方法对纳入文献进行资料提取和质量评价,采用Rev Man 5.2统计软件进行Meta分析,比较非索非那定与西替利嗪治疗AR患者治疗后总症状评分、总有效率及不良事件发生率。结果共纳入10篇RCT,共2 165例患者。Meta分析结果显示,试验组与对照组患者治疗后总症状评分比较,差异无统计学意义〔加权均数差(WMD)=-0.33,95%CI(-0.77,0.11),P=0.14〕;试验组总有效率高于对照组〔优势比(OR)=1.76,95%CI(1.27,2.44),P=0.000 6〕;试验组与对照组患者不良事件发生率比较,差异无统计学意义〔相对危险度(RR)=1.08,95%CI(0.93,1.25),P=0.32〕。结论与西替利嗪比较,非索非那定治疗AR可以改善患者的总有效率,而不良事件风险相当。受纳入文献数量和质量所限,上述结论尚待开展更多大样本、多中心的高质量文献进行验证。
[Abstract]:Objective to evaluate the efficacy and safety of fexofenadine and cetirizine in the treatment of allergic rhinitis (AR). Methods Pub Med,EMBase,Cochrane Library, China knowledge Network was searched by computer. The (RCT), retrieval time of the clinical randomized controlled trial (RCT),) about the treatment of AR by fexofenadine (trial group) and cetirizine (control group) in WebNet and Wanfang data knowledge service platform was built up to 2016-06-10. According to the evaluation method of Cochrane system, the retrieval time of (RCT), was compared. Enter the literature for data extraction and quality evaluation, The total symptom score, total effective rate and incidence of adverse events of patients with AR treated with fexofenadine and cetirizine were compared by using Rev Man 5.2 statistical software for Meta analysis. Results the results of Meta-analysis showed that there was no significant difference in total symptom scores between the trial group and the control group after treatment (weighted mean difference (WMD) -0.33 95 CI (-0.77 卤0.11) P0. 14). The total effective rate in the trial group was higher than that in the control group (the odds ratio was (OR) 1.76 / 95 CI (1.272.44) / P 0.000 6), and there was no significant difference in the incidence of adverse events between the trial group and the control group (relative risk (RR) 1.0895 CI (0.931.25) P 0.32). Conclusion compared with cetirizine, fexofenadine can improve the total effective rate of patients with AR, and the risk of adverse events is equal. Limited by the quantity and quality of the literature included, the above conclusions need to be verified by more large samples and high quality literatures with multiple centers.
【作者单位】：西南医科大学附属医院药剂科;西南医科大学药学院;
【分类号】：R765.21

【相似文献】